SCHEMBL30133689

SCHEMBL30133689

CC(C)(C)OC(=O)N[C@@H](Cc1ccccc1Cl)c1ccn(C(F)F)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 1/20 0.39
▸ SCN10A Q9Y5Y9 1/20 0.39
▸ CTSK P43235 3/20 0.38
▸ CTSS P25774 2/20 0.38
▸ LMNA P02545 3/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ TSHR P16473 2/20 0.37
▸ MC4R P32245 1/20 0.37
▸ AKT1 P31749 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ XBP1 P17861 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ NPSR1 Q6W5P4 2/20 0.36
▸ SSTR3 P32745 1/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ S1PR4 O95977 1/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29168234 1.00 SCN9A (0.39) SCN9ASCN10ACTSKCTSSLMNA
SCHEMBL30133666 0.82 CTSL (0.50) SCN9ACTSKCTSSLMNAMEN1
SCHEMBL29168065 0.82 MAPK1 (0.39) CTSKCTSSLMNAMEN1KMT2A
SCHEMBL29168067 0.82 MAPK1 (0.39) CTSKCTSSLMNAMEN1KMT2A
SCHEMBL30133692 0.82 MAPK1 (0.39) CTSKCTSSLMNAMEN1KMT2A
SCHEMBL29168151 0.80 MEN1 (0.38) LMNAMEN1KMT2ATSHRAKT1
SCHEMBL29168149 0.80 MEN1 (0.38) LMNAMEN1KMT2ATSHRAKT1
SCHEMBL30133676 0.78 SSTR3 (0.41) SCN9ASCN10ACTSKCTSSLMNA
SCHEMBL29168052 0.78 SSTR3 (0.41) SCN9ASCN10ACTSKCTSSLMNA
SCHEMBL29168232 0.78 SMN1; SMN2 (0.36) LMNAMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2024-09-12 — — US disclosed
EP-4352049-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Avelos Therapeutics Inc. (KR) 2024-04-17 — — EP disclosed
CN-117529476-A Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments 亚飞络思制药公司 2024-02-06 — — CN disclosed
WO-2022260441-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS AVELOS THERAPEUTICS INC. (KR) 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300936-A1 PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS MAST1, MAST3, MAST4 SCN9A 3721/4885SCN10A 3944/4885CTSK 580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback